enow.com Web Search

  1. Ads

    related to: neuromyelitis optica treatments fda approved prescription

Search results

  1. Results from the WOW.Com Content Network
  2. Inebilizumab - Wikipedia

    en.wikipedia.org/wiki/Inebilizumab

    Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. [8] [9] [5] Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells.

  3. Eculizumab - Wikipedia

    en.wikipedia.org/wiki/Eculizumab

    Health Canada approved it in 2009, to treat paroxysmal nocturnal hemoglobinuria and in 2013, as the only drug to treat atypical hemolytic uremic syndrome. [ 25 ] Eculizumab was approved by the FDA for the treatment of adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 (AQP4) antibody positive in 2019, based on the ...

  4. Neuromyelitis optica spectrum disorder - Wikipedia

    en.wikipedia.org/wiki/Neuromyelitis_optica...

    Neuromyelitis optica (NMO) is a particular disease within the NMOSD spectrum. It is characterised by optic neuritis and longitudinally extensive myelitis. In more than 80% of NMO cases, the cause is immunoglobulin G autoantibodies to aquaporin 4 ( anti-AQP4 ), the most abundant water channel protein in the central nervous system.

  5. Satralizumab - Wikipedia

    en.wikipedia.org/wiki/Satralizumab

    The effectiveness and safety of satralizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD) were demonstrated in two 96-week clinical studies. [ 6 ] [ 8 ] [ 15 ] [ 17 ] [ 18 ] A study of satralizumab as monotherapy for NMOSD [ 17 ] included 95 adult participants, 64 of whom had antibodies against AQP4 (i.e. were anti-AQP4 ...

  6. List of therapeutic monoclonal antibodies - Wikipedia

    en.wikipedia.org/wiki/List_of_therapeutic...

    This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.

  7. List of drugs granted breakthrough therapy designation

    en.wikipedia.org/wiki/List_of_drugs_granted...

    In combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adults with locally advanced or metastatic non- small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [2] Tagrisso: Treatment of adults with locally advanced, unresectable ...

  8. Ocrelizumab/hyaluronidase - Wikipedia

    en.wikipedia.org/wiki/Ocrelizumab/hyaluronidase

    Clinical trial number NCT05232825 for "A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (Ocarina II)" at ClinicalTrials.gov

  9. Azathioprine - Wikipedia

    en.wikipedia.org/wiki/Azathioprine

    Azathioprine is used alone or in combination with other immunosuppressive therapy to prevent rejection following organ transplantation, and to treat an array of autoimmune diseases, including rheumatoid arthritis, pemphigus, systemic lupus erythematosus, Behçet's disease, and other forms of vasculitis, autoimmune hepatitis, atopic dermatitis, myasthenia gravis, neuromyelitis optica (Devic's ...

  1. Ads

    related to: neuromyelitis optica treatments fda approved prescription